About Us

Who are we: MYLeukaemia is an evidence-driven, Madeira-based spinoff advancing functional precision oncology for blood cancers - starting with AML & scaling to other blood cancers. Our Therapy Guidance Chipset recreates the bone-marrow niche (vascular and endosteal cues) on a microfluidic Organ-on-Chip, so we can observe how a patient’s cells respond to approved drug options before treatment begins. The aim: a ranked therapy report in ~72 hours that fits existing lab workflows.

Where we come from: The platform grew from two years of funded research at i3S / University of Porto. We’ve been recognized with early awards and selection to deep-tech programs, which helps - but our focus is disciplined execution, clinical proof, and patient benefit.

What’s next: We’re progressing from TRL-4 toward TRL-6 with prospective pilots. If you lead a haematology service, a reference lab network, or a pharma program in heme-oncology, we’d love to collaborate on validation, logistics integration, and clinical utility studies.

MYLeukaemia is under clinical validation and not yet a commercially available diagnostic. Results are provided for research/clinical-assessment use within applicable regulations.